Effect of Meibomian Gland Related Therapy on the Morphology of Meibomian Gland

Sponsor
Yune Zhao (Other)
Overall Status
Withdrawn
CT.gov ID
NCT04636372
Collaborator
(none)
0
3
5

Study Details

Study Description

Brief Summary

200 participants at Eye Hospital of Wenzhou Medical University during September, 2020 to November, 2020 will be enrolled in this study. The meibomian gland related therapy are pulsed light therapy and meibomian gland hot compress massage.

Condition or Disease Intervention/Treatment Phase
  • Device: Intense pulsed light therapy
  • Other: Hot compress massage
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effect of Meibomian Gland Related Therapy on the Morphology of Meibomian Gland
Anticipated Study Start Date :
Sep 1, 2020
Anticipated Primary Completion Date :
Jan 31, 2021
Anticipated Study Completion Date :
Jan 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intense pulsed light therapy group

Device: Intense pulsed light therapy
Patients with xerophthalmia were treated with intense pulsed light of meibomian gland.

Experimental: Hot compress massage group

Other: Hot compress massage
Patients with xerophthalmia were treated with hot compress massage of meibomian gland.

Experimental: Intense pulsed light therapy and hot compress massage group

Device: Intense pulsed light therapy
Patients with xerophthalmia were treated with intense pulsed light of meibomian gland.

Other: Hot compress massage
Patients with xerophthalmia were treated with hot compress massage of meibomian gland.

Outcome Measures

Primary Outcome Measures

  1. The length of meibomian glands after the treatment. [up to 2 months]

    Length in millimeters.

  2. The area of meibomian glands after the treatment. [up to 2 months]

    Area in millimeters^2.

  3. The percentage of meibomian glands after the treatment. [up to 2 months]

    Percentage of meibomian glands in %(area of meibomian glands (mm^2) and area of palpebral conjunctiva (mm^2) will be combined to report percentage of meibomian glands in %) are used to assess this outcome measure.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Previously untreated patients with xerophthalmia
Exclusion Criteria:
  • No history of ocular surgery and trauma

  • Any eye diseases except xerophthalmia

  • No treated for xerophthalmia before

  • Successful completion of follow-ups

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Yune Zhao

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yune Zhao, Vice president of Eye Hospital of Wenzhou Medical University, Wenzhou Medical University
ClinicalTrials.gov Identifier:
NCT04636372
Other Study ID Numbers:
  • LXY-meibomian gland
First Posted:
Nov 19, 2020
Last Update Posted:
Nov 19, 2020
Last Verified:
Sep 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 19, 2020